The Safety of Proctofoam-HC in the Third Trimester of Pregnancy
|ClinicalTrials.gov Identifier: NCT00405288|
Recruitment Status : Completed
First Posted : November 30, 2006
Results First Posted : February 5, 2014
Last Update Posted : February 5, 2014
|Condition or disease||Intervention/treatment|
|Hemorrhoids Pregnancy||Drug: Proctofoam-HC®|
Hemorrhoids are a frequent condition in pregnancy. The rate is increased as pregnancy progresses, and they affect up to 24% of pregnant women in the third trimester. Complications of untreated hemorrhoids include bleeding, prolapse, soiling, discharge with perianal irritation and itching, and in severe cases, severe pain and venous engorgement which could even lead to thrombosis and infarction. Hemorrhoids are treated with a variety of suppositories and gels, based on analgesic and anti-inflammatory effects. The safety of these antihemorrhoidal products has not yet been documented in pregnant women.
Proctofoam-HC® has been on the Canadian market for 25 years. It combines the anti-inflammatory action of hydrocortisone with the surface anesthetic effect of pramoxine HCl. It is approved for temporary relief of anorectal inflammation, pruritus, pain and swelling associated with haemorrhoids, fissures, pruritus ani, cryptitis, proctitis and postoperative pain.
We hypothesize that local application of Proctofoam-HC® in the third trimester of pregnancy is safe for the mother and fetus.
|Study Type :||Observational|
|Actual Enrollment :||408 participants|
|Observational Model:||Case Control|
|Official Title:||The Safety of Proctofoam-HC in the Third Trimester of Pregnancy|
|Study Start Date :||November 2006|
|Actual Primary Completion Date :||November 2009|
|Actual Study Completion Date :||June 2010|
Women in the third trimester of pregnancy prescribed Proctofoam-HC® aerosol foam canister for 36 applications for treatment of symptoms of hemorrhoids. One applicatorful is to be applied into the anus (or on the perianal area) two or three times daily and after bowel evacuation.
Observational study of the exposure to Proctofoam-HC®
Other Name: 1% Pramoxine+1% Hydrocortisone ( Proctofoam-HC®)
Control group of women in the third trimester of pregnancy who were not exposed to any teratogens during the course of the pregnancy, and to Proctofoam-HC any of its components, or any other topical corticosteroids or local anaesthetics during the course of their pregnancy.
- Birth-weight [ Time Frame: until delivery ]Weight of the baby measured in grams at time of birth.
- Gestational Age at Delivery [ Time Frame: until delivery ]Fetal gestational age at delivery
- Mode of Delivery [ Time Frame: at birth ]Method of delivery for both groups: vaginal or caesarean section
- Prematurity [ Time Frame: at birth ]birth at <37 gestational weeks
- Fetal Distress [ Time Frame: at birth ]Presence of fetal distress at birth: heart deceleration/acceleration, meconium/amniotic fluid
- Low Birth Weight at Birth [ Time Frame: at birth ]Low birth weight (birth weights <2500 grams)
- Neonatal Health [ Time Frame: at birth ]Neonatal health at birthyes=need for medical attention or intervention after birth, abnormalities detected, no= no need for medical attention, no abnormalities detected at birth
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00405288
|Mount Sinai Hospital|
|Toronto, Ontario, Canada, M5G 1X5|
|The Hospital for Sick Children|
|Toronto, Ontario, Canada, M5G 1X8|
|Principal Investigator:||Gideon Koren, MD||The Hospital for Sick Children, Toronto Canada|